| Authors: |
Tuval A; Department of Immunology, Weizmann Institute of Science, Rehovot, Israel; Department of Hematology, Meir Medical Center, Kfar Saba., Brilon Y; Department of Immunology, Weizmann Institute of Science, Rehovot., Azogy H; Department of Immunology, Weizmann Institute of Science, Rehovot, Israel; Department of Pathology, Sackler Faculty of Medicine, Aviv University, Aviv., Moskovitz Y; Department of Immunology, Weizmann Institute of Science, Rehovot., Leshkowitz D; Department of Life Sciences Core Facilities, Weizmann Institute of Science, Rehovot., Salame TM; Department of Life Sciences Core Facilities, Weizmann Institute of Science, Rehovot., Minden MD; Princess Margaret Cancer Centre, University Health Network (UHN), Toronto, Ontario, Canada; Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Division of Medical Oncology and Hematology, University Health Network, Toronto, Ontario, Canada; Department of Medical Biophysics, University of Toronto, Toronto, Ontario., Tal P; Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot., Rotter V; Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot., Oren M; Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot., Kaushansky N; Department of Immunology, Weizmann Institute of Science, Rehovot., Shlush LI; Department of Immunology, Weizmann Institute of Science, Rehovot, Israel; Division of Hematology, Rambam Health Care Campus, Haifa, Israel; Molecular Hematology Clinic, Maccabi Healthcare Services, Aviv. liran.shlush@weizmann.ac.il. |
